Navigation Links
Aureus Pharma Releases AurPROFILER(R) - a New and Powerful Pharmacology Profiling Solution
Date:8/18/2008

PARIS, August 18 /PRNewswire/ -- Aureus Pharma, a leading provider of knowledge management solutions that accelerate life science discovery, announced the release today of the new software solution AurPROFILER(R).

AurPROFILER enables researchers to rapidly evaluate target, cell and drug profiles using bio-assays derived from the activity data found in Aureus Pharma's AurSCOPE Target Knowledge databases. AurPROFILER has been designed to work in conjunction with the just released AurSCOPE(R) Global Pharmacology Space and all of Aureus' drug target focused knowledge databases.

Compound profiling is routinely used by pharmaceutical researchers to evaluate the critical issues of drug target selectivity including off-target effects, polypharmacology and cytotoxicity. With easily interpretable graphics, AurPROFILER provides valuable insights to help better manage these issues by rapidly providing in-silico profiles. AurPROFILER results facilitate better discovery team decision making, and reduce risk to that streamline drug discovery projects. AurPROFILER was developed in collaboration with a pharmaceutical industry focus group consisting of several major pharmaceutical companies.

"After intensive development and customer validation, we are delighted to release AurPROFILER." said Jason Theodosiou, President and CEO of Aureus Pharma. "AurPROFILER is an example where the combination of Aureus' analysis capabilities and the high quality data within AurSCOPE Knowledge databases combine to bring additional value to researchers."

Aureus Pharma experts will demonstrate AurPROFILER at the American Chemical Society (ACS) meeting in Philadelphia, PA August 18th -21st.

About Aureus Pharma

Aureus Pharma headquartered in Paris, France is a privately held knowledge management based solutions provider for the life sciences industry. Aureus Pharma accelerates new drug discovery by providing knowledge databases which contain high quality qua
'/>"/>

SOURCE Aureus Pharma
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. New ActivePure Technology Proven To Reduce Exposure to Methicillin Resistant Staphylococcus Aureus (MRSA)
2. Aureus Pharma Announces Renewal and Expansion of Licensing Agreement With Bristol-Myers Squibb for its AurSCOPE Knowledge Databases
3. QSB Anti-Virulence Platform Inhibits Biofilm Formation by Staphylococcus Aureus MRSA and Candida sp
4. Aureus Pharma Announces Date of 2008 Annual User Symposium
5. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
6. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
7. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
8. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
9. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
10. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... light, rather than electricity, to move data would ... is a growing concern as chips, transistor counts ... optical circuits light emitters, modulators, and detectors ... promising light source for optical chips is molybdenum ... deposited as a single, atom-thick layer. Other experimental ...
(Date:9/19/2014)... 19, 2014  An entire month is dedicated to ... – Charcot-Marie-Tooth disease (CMT) – a debilitating neuromuscular disease ... muscle atrophy, weakness, and foot and hand deformities. CMT ... worldwide. CMT is a progressive disease, and over time ... mobility devices such as leg braces, wheelchairs and scooters ...
(Date:9/19/2014)... 19, 2014  Nektar Therapeutics (NASDAQ: ... characterizing the analgesic profiles of a series of ... agonist molecules. The preclinical research candidates were created ... The analgesic properties of kappa receptor ... 1,2 Kappa opioid receptors are expressed in ...
(Date:9/19/2014)... SPRINGS, Florida , September 19, 2014 ... companies release latest developments, patents and results of studies ... GNSZ), Eli Lilly and Company (NYSE: LLY ... Celgene Corporation (NASDAQ: CELG ) and Arena ... GNSZ), a leader in developing prodrug therapeutics for the ...
Breaking Biology Technology:Toward optical chips 2Toward optical chips 3September is Charcot-Marie-Tooth (CMT) Awareness Month - Scheduled events, activities and important partnerships announced throughout the month! 2Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 2Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 3Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 4Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 5Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 2Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 3Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 4Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 5Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 6Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 7
... SAN DIEGO, Oct. 28 Neurocrine Biosciences,(Nasdaq: NBIX ) announces the ... 2008 Financial Results, When: October 28, 2008 @ ... http://www.videonewswire.com/event.asp?id=52783 , How: Live over the Internet ... above., Contact: Claudia ...
... U.S. Phase II Study,of Nitazoxanide in Treatment-Naive Patients ... Oct. 28 Romark Laboratories, a privately,held biopharmaceutical ... at the upcoming 59th Annual Meeting of the ... also known as The,Liver Meeting(R), and the 50th ...
... Ziplex automated gene-expression system at the ... ... Molecular, a pioneer in,the development of cost-effective, easy-to-use gene-expression analysis,systems, ... L. Wittliff, a professor in the Department of,Biochemistry and Molecular ...
Cached Biology Technology:Romark Laboratories Announces Presentation of New Nitazoxanide Data at 59th Annual AASLD Meeting and 50th Anniversary IASL Meeting in San Francisco 2James L. Wittliff, Ph.D., FACB, to Present 'Predicting Breast Cancer Outcome with Gene Expression Signatures on the Ziplex(R) System' at the Association for Molecular Pathology Conference, October 30 2James L. Wittliff, Ph.D., FACB, to Present 'Predicting Breast Cancer Outcome with Gene Expression Signatures on the Ziplex(R) System' at the Association for Molecular Pathology Conference, October 30 3
(Date:9/18/2014)... in DNA, tiny strands of nucleic acid that contain ... this genetic data, our DNA is copied into RNA ... perform tasks in our cells. , Several years ... Unlike all other known RNAs, this molecule is circular, ... abundant, little has been known about how they are ...
(Date:9/18/2014)... ALEXANDRIA, Va.Sept. 18, 2014Many Americans across racial and ... the greatest impact on their day-to-day life, more ... memory, hearing and speech (57% of African-Americans, 49% ... of Hispanics). When asked which disease or ailment ... blindness ranked first among African-Americans followed by AIDS/HIV. ...
(Date:9/18/2014)... have devastated algal forests in the eastern Mediterranean Sea ... if their distribution continues to expand as the climate ... international team of researchers led by Dr Adriana Vergs ... Mediterranean Institute for Advanced Studies in Spain, is published ... the team surveyed more than 1000 kilometres of coastline ...
Breaking Biology News(10 mins):Scientists find how mysterious 'circular RNA' is formed, claim muscular dystrophy link 2Americans rate losing eyesight as having greatest impact on their lives 2Americans rate losing eyesight as having greatest impact on their lives 3Tropical fish a threat to Mediterranean Sea ecosystems 2
... of life -- kids get sick and have fevers. ... but in some small children they spark convulsions called ... very upsetting to parents," said Robert L. Macdonald, M.D., ... something of an enigma, he said. The epilepsy research ...
... development of drug-resistant HIV when patients take as few as ... only when patients take most of their pills. These differences ... "fitness" of the drug-resistant HIV, say AIDS researchers in a ... MPH, an AIDS specialist at the University of California, San ...
... Vaccine and Infectious Disease Organization (VIDO) have developed a vaccine ... against a disease for which no vaccines are yet available. ... this vaccination technique may be effective against HCV. The study ... , The team, funded by the Canadian Institutes of Health ...
Cached Biology News:Molecular mechanism may explain how fevers spark seizures 2Molecular mechanism may explain how fevers spark seizures 3Viral 'fitness' explains different resistance patterns to aids drugs 2U of S researchers develop new vaccine candidate against hepatitis C 2
... EVO96R and Freedom EVO384R are fast multi-channel ... in three different sizes, with a multi-channel ... deliver significant time saving, with true parallel ... setup of your assays with the Freedom ...
... are fast multi-channel pipetting platforms consisting of ... with a multi-channel head and a robotic ... with true parallel processing of sample plates ... with the Freedom EVOware program. ...
Prepared by multi-temperature ethanol fractionation with extensive charcoal treatment and dialysis.• Assay: ≥ 95 % (HPCE)• pH ~5.2 (10 mg/mL in 0.15 M NaCl)...
... Linkage: This CLS number is a ... match Cornings product number. If showing ... the old Sigma-Aldrich number (Z71,405-4) or ... Dim: diam. 60 mm volume ...
Biology Products: